Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSBR-1290 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1: GSBR-1290 or Placebo | EXPERIMENTAL | Healthy Japanese participants will receive once daily doses of study drug (GSBR-1290 or placebo oral capsules) for up to 4 weeks. |
| Cohort 2: GSBR-1290 | EXPERIMENTAL | Healthy non-Japanese participants (Caucasians or African Americans) will receive once daily doses of study drug (GSBR-1290 oral capsules) for up to 4 weeks. |
| Cohort 1 | EXPERIMENTAL | Patients will receive once daily doses of study drug (GSBR-1290 or Placebo) for a total of 4 weeks |
| Cohort 2 | EXPERIMENTAL | Patients will receive once daily doses of study drug (GSBR-1290 or Placebo) for a total of 4 weeks |
| Cohort 3 | EXPERIMENTAL | Patients will receive once daily doses of study drug (GSBR-1290 or Placebo) for a total of 4 weeks |
| Cohort 4 | EXPERIMENTAL | HOV participants (Cohort 4) will receive multiple-ascending doses of GSBR-1290 or placebo for a total of 12 weeks |
| Cohort 5 | EXPERIMENTAL | Participants with T2DM(Cohort 5) will be randomized to placebo, low-dose, or high-dose arms. Participants in the low-dose, high-dose or placebo arms will receive multiple-ascending doses for 12 weeks |
| Name | Type | Description |
|---|---|---|
| GSBR-1290 | DRUG | Participants will receive GSBR-1290 oral capsules. |
| Placebo | OTHER | Participants will receive matching placebo oral capsules. |
Inclusion Criteria: For Cohort 1 only: 1. Japanese participants must have both parents and 4 grandparents of Japanese origin For Cohort 2 only: 2. Non-Japanese participants must not have parents and grandparents of Japanese origin. Non-Japanese participants will be limited to Caucasians of Eur...
GSBR-1290 is an investigational small molecule being studied for overweight or obesity and type 2 diabetes mellitus. It is also being evaluated in healthy volunteers to assess safety and tolerability. The drug is in Phase 1 clinical development and is not yet approved by regulatory authorities.
GSBR-1290 is being developed by Structure Therapeutics Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol GPCR. The company is conducting clinical trials to evaluate the drug's safety, tolerability, and potential efficacy in the intended patient populations.
GSBR-1290 is currently in Phase 1 clinical development. Two Phase 1 studies have been completed, including a Phase 1b/2a study in overweight or obese subjects and subjects with type 2 diabetes mellitus, and a multiple ascending dose study in healthy participants. The drug remains investigational and has not received FDA approval.
GSBR-1290 has been studied in two completed clinical trials. The first, NCT05762471, was a Phase 1b/2a study in 142 overweight or obese adults and subjects with type 2 diabetes mellitus in the United States. The second, NCT05893043, was a multiple ascending dose study in 18 healthy Japanese and non-Japanese participants.
GSBR-1290 is a small molecule designed to target specific biological pathways involved in metabolic regulation. While the exact molecular target is not publicly detailed, the drug is being investigated for its effects on weight management and glycemic control in conditions such as obesity and type 2 diabetes.